AFT — AFT Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapHigh Flyer

Annual income statement for AFT Pharmaceuticals, fiscal year end - March 31st, NZD millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	130	157	195	208	255
Cost of Revenue
Gross Profit	61.8	73	88.3	91.7	111
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	110	137	171	190	230
Operating Profit	20.4	19.7	24.2	17.6	24.4
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	18.7	15.8	22	16	21.9
Provision for Income Taxes
Net Income After Taxes	19.8	10.7	15.6	11.4	14.1
Minority Interest
Net Income Before Extraordinary Items
Net Income	19.8	10.7	15.6	12	14.7
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	19.8	10.7	15.6	12	14.7
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.19	0.102	0.149	0.114	0.14
Dividends per Share
Special Dividends per Share